Please assess the completion status of the following clinical trial:

Trial Title: Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed renal cell carcinoma (primary tumour or biopsy/surgery of metastases)~* Radiologically confirmed metastatic disease~* Surgically removed primary tumour so feasible (nephrectomy or nephron-sparing surgery as indicated)~* Karnofsky-Performance Status \>70%~* Age 19-75 years~* Life expectancy of at least 3 months~* Adequate bone marrow function (i.e. white blood cell count above 3000/μL, platelet count above 75 000 /μL, hemoglobin above 9 mg/dl)~* Adequate organ function (i.e. serum creatinine, bilirubin and AST below 1.25 x the upper limit of the institutions' normal range)~* Negative pregnancy test for female patients~* Written informed consent~Exclusion Criteria:~* Age \<19 or \>75 years~* Karnofsky-Performance Status \< 70%~* Untreated or uncontrolled brain metastases~* Second neoplasia~* Primary tumour surgically removable~* Solitary, surgically removable metastases~* Major concomitant diseases of the cardiovascular, respiratory or renal systems, as well as active systemic infections~* Severe renal disease or liver insufficiency or myeloid dysfunction (including patients with a history of a disease that is likely to interfere with the metabolism or excretion of the test medication)~* Other less common diseases as peptic ulcer disease, inflammatory bowel disease, autoimmune disease (severe known psoriasis, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, rheumatoid arthritis etc.)~* Drug addiction (including excessive alcohol consumption) within 1 year prior to study start.~* History of other conditions consistent with decompensated liver disease or other evidence of bleeding form esophageal varices.~* History of chronic hepatitis and immunsupressiva~* Known HIV Infection~* Evidence of allergy or hypersensitivity against recombinant Interferon alfa-2a or other components of preparation.~* History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time or any history of the following: a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease.~* Seizure disorders and /or compromised central nervous system function.~* History of evidence of severe retinopathy~* Patient unwilling or unable to give informed consent~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Capecitabine and Interferon (Type: ACTIVE_COMPARATOR): Combined Chemo-Immunotherapy Chemotherapy: Mo-Fr Immunotherapy
- Interferon (Type: ACTIVE_COMPARATOR): Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.~Efficacy evaluations will be performed every 14 weeks of treatment in both groups

Based on this trial design, predict the completion outcome and termination type (if applicable).